Chris Degnan

Chris Degnan currently serves as the Chief Financial Officer at UroGen Pharma, a position held since October 2024. Prior to this role, Chris held the same title at Galera Therapeutics, Inc. from October 2019 to August 2024, and at Verrica Pharmaceuticals from March 2018 to October 2019. Additional experience includes various finance leadership roles at Endo Pharmaceuticals from November 2014 to March 2018, and a significant tenure at AstraZeneca from May 2004 to November 2014, where Chris progressed through several finance-related positions. Early in the career, Chris gained experience as a Senior Accountant at KPMG LLP between August 2001 and May 2004. Chris earned a Bachelor of Business Administration in Accounting from the University of Notre Dame, attending from 1997 to 2001, and completed secondary education at Salesianum High School from 1993 to 1997.